In Stock Cell Lines
Homo sapiens (Human)
Liver
Adherent
The GDF1 Knockout Hep 3B2.1-7 Cell Line is a CRISPR/Cas9-edited human hepatocellular carcinoma knockout line featuring disruption of GDF1, a TGF-beta superfamily ligand that heterodimerizes with Nodal to activate SMAD2/3 signaling. The parental Hep 3B2.1-7 line harbors an integrated hepatitis B virus genome and constitutively expresses HBsAg and AFP, providing a well-established model for liver cancer and HBV research. This GDF1 knockout line enables functional studies of left-right asymmetry and TGF-beta signaling in a hepatic context. Key downstream targets include PITX2 and LEFTY1, and pathway activity can be monitored by phospho-SMAD2/3 detection. Typical applications encompass developmental biology research, congenital heart disease modeling, and hepatocarcinogenesis investigations.
MSH3 Knockout A549 Polyclonal Cells
Cat. No. ARG10807
ACY1 Knockout 786-O Polyclonal Cells
Cat. No. ARG24818
ANG Knockout A549 Polyclonal Cells
Cat. No. ARG38711
DOCK9 Knockout Hela Polyclonal Cells
Cat. No. ARG39623
PAGR1 Knockout A549 Polyclonal Cells
Cat. No. ARG9932
P3H1 Knockout Raji Polyclonal Cells
Cat. No. ARG1658
The GDF1 Knockout Hep 3B2.1-7 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the Hep 3B2.1-7 human hepatocellular carcinoma line. It features targeted disruption of GDF1, which encodes a TGF-beta superfamily ligand essential for embryonic left-right axis determination and heart development. Offered as a ready-to-use cell line, it circumvents the need for de novo gene editing and allows researchers to immediately interrogate GDF1 function in signal transduction and developmental biology.
The host Hep 3B2.1-7 cells are a subclone of Hep 3B, established from a liver tumor of an 8-year-old Black male. This line carries an integrated hepatitis B virus genome and expresses HBV surface antigen and alpha-fetoprotein, making it a standard model for hepatotoxicity, HBV pathogenesis, and liver cancer studies. Its robust in vitro growth and retention of hepatic features support diverse applications from toxicology to oncogenic signaling.
GDF1 heterodimerizes with Nodal to activate activin type I and II receptors (ACVR1B, ACVR2A/B), inducing phosphorylation of SMAD2 and SMAD3. Phosphorylated SMAD2/3 complexes with SMAD4 and translocate to the nucleus to regulate transcription of key targets including PITX2, LEFTY1/2, and CER1. This cascade is modulated by upstream regulators FOXH1 and TDGF1 (Cripto-1) and antagonized by Lefty and Cerberus. Through these interactions, GDF1 directs visceral organ asymmetry and cardiac morphogenesis.
In the hepatocellular carcinoma background of Hep 3B2.1-7, GDF1 knockout provides a unique tool to study TGF-beta superfamily signaling in liver cancer. Disrupting GDF1 may impact SMAD-mediated transcriptional programs, influencing tumor cell proliferation, migration, and response to growth factors. Moreover, with its HBV integration, this model facilitates exploration of GDF1??s role in virus?Chost interactions. It also serves as a relevant in vitro system for congenital heart disease and heterotaxy research, bridging developmental biology and cancer contexts.
This cell line is well-suited for functional assays such as western blotting for phospho-SMAD2/3, RT-qPCR measurement of PITX2 and LEFTY1 expression, and immunofluorescence tracking of SMAD2/3 localization. Reporter assays with SMAD-responsive elements can quantify pathway activity, while flow cytometry assesses activin receptor levels. Migration and invasion assays enable phenotypic characterization. Researchers can apply this model for pooled screening and co-culture experiments. For further information, contact Ascent Research.
